Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It is assumed that hepatobiliary, cell-specific contrast agents will be adversely affected by the presence of diffuse liver disease. The diagnostic efficacy for tumor detection in the presence of
fatty liver
disease was experimentally studied at contrast-enhanced magnetic resonance (MR) imaging with manganese-DPDP (N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis[phosphate]) and gadobenate dimeglumine (
Gd-BOPTA
/dimeg) and compared with conventional and chemical shift imaging. Carcinosarcoma was implanted into the liver of rats, and
fatty liver
was induced with L-ethionine. Without contrast agents, the tumor-
fatty liver
contrast-to-noise ratio (C/N) was increased on T1-weighted and decreased on T2-weighted MR images relative to tumor-bearing control rats without
fatty liver
. Chemical shift imaging (phase-contrast method) increased the tumor-
fatty liver
C/N from 2.3 +/- 1.0 to 6.1 +/- 1.7 (P < .001). Mn-DPDP and
Gd-BOPTA
/dimeg increased the tumor-
fatty liver
C/N from -5.4 +/- 1.6 to -11.0 +/- 1.9 and -9.8 +/- 3.4, respectively (P < .001). The hepatobiliary, cell-specific contrast agents were equally effective in both fatty and non-
fatty liver
and outperformed both chemical shift and conventional MR imaging in detecting liver tumors.
...
PMID:Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents. 806 31
The purpose of this study was to determine the practicability and diagnostic accuracy of a magnetic resonance (MR) protocol capable of replacing computed tomography, catheter angiography, and endoscopic retrograde cholangiopancreatography for the presurgical evaluation of potential liver donors before right hepatectomy. MR imaging (MRI) was performed on a 1.5 T scanner using a phased-array torso surface coil for signal reception. The following image sets were collected: axial two-dimensional (2D) T1-weighted fast low angle shot (FLASH), axial 2D T2-weighted half-Fourier acquisition single-shot turbo-spin-echo (HASTE) with fat saturation, coronal MR cholangio-pancreatography (MRCP) based on 2D multisection HASTE and single-section single-shot rapid acquisition with relaxation enhancement (RARE) imaging, dynamic contrast-enhanced three-dimensional (3D) FLASH, and contrast-enhanced T1-weighted FLASH. 3D FLASH data sets were collected before and after an intravenous administration of
Multihance
(gadobenate dimeglumine,
Gd-BOPTA
; Bracco, Milano, Italy), 0.2 mmol/kg of body weight. Thirty-eight potential liver donors were assessed by means of MRI. Twenty patients also underwent digital subtraction angiography (DSA). Of these, 16 patients underwent liver harvesting. MR angiography (MRA) data sets correlated with DSA results, and MRCP results correlated with intraoperative findings. Patients were excluded as potential donors based on insufficient liver mass of the left hepatic lobe (n = 5) or presence of hepatic pathological states (n = 9) seen at MRI, such as hemangiomas, focal nodular hyperplasias, or
hepatic steatosis
. MRCP showed the biliary system to the level of the first hepatic side branch. Dilated ducts were present in 4 patients. MRA depiction of hepatic arterial morphological characteristics correlated with catheter angiography results in all 20 patients: Three left hepatic arteries originating from the left gastric artery, three aberrant right hepatic arteries originating from the superior mesenteric artery, and two aberrant origins of both hepatic arteries and one common hepatic artery originating from the superior mesenteric artery were correctly identified on MRA. Similarly, the portal venous system was fully assessed on MRA. A comprehensive assessment of the hepatic parenchyma, biliary and pancreatic ductal system, and hepatic arterial, portal, and venous systems can be accomplished using the outlined protocol.
...
PMID:Right-lobe living related liver transplantation: evaluation of a comprehensive magnetic resonance imaging protocol for assessing potential donors. 1191 May 69
We report a case of pathologically confirmed multinodular focal fatty infiltration. MRI was performed after bolus injection of gadobenate dimeglumine (
Gd-BOPTA
, MultiHance; Bracco, Milan, Italy), a liver-specific paramagnetic, gadolinium (Gd)-based MR contrast agent that concomitantly enables the acquisition of a standard dynamic phase with timing strategies similar to those used for other extracellular fluid contrast agents, followed by a delayed T1-weighted liver-specific phase (the so-called hepatobiliary phase). In the present case, multiple rounded areas of fatty infiltration, although confidently diagnosed using chemical shift sequences due to a significant signal intensity reduction on out-of-phase images, were unexpectedly hypointense during the delayed liver-specific phase of
Gd-BOPTA
. Reduced
Gd-BOPTA
concentration during the liver-specific phase is generally correlated with liver malignancy. Since such lesions can be prospectively mistaken for metastatic disease, we performed a hepatic biopsy to establish a definitive diagnosis. Our empirical observations suggest that
Gd-BOPTA
uptake may be impaired in fatty infiltrated liver tissue. Because at present there is no report evaluating the kinetics of
Gd-BOPTA
in
fatty liver
, further studies are needed to specifically investigate this issue.
...
PMID:Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. 1687 4